On 2/15/2024, Alkermes (ALKS) reported earnings of $0.59 per share on revenue of $377.48 million for the fourth quarter ended December 2023. The consensus earnings estimate was $0.54 per share on revenue of $362.02 million.
History doesn't repeat itself but it often rhymes. And in the stock market, more specifically with technical analysis, we are able to understand why price moved the way it did in the past and, if it's doing something similar again, what to expect. So here, we see repeated controlled selling channels (magenta) being used to build liquidity for buyers. We also...
Heres a hindsight view of the ALKS breakout this morning which was in correlation with it announcing earnings. But putting aside the fundamentals of the company, here we focus on technical analysis and how we were prepared for this breakout. Happy Trading!
An example of an Ascending Triangle on a Monthly timeframe Ascending Triangles tend to break out bullishly which I have shown with the bars pattern tool A big Breakout for a completion of a big chart pattern Bullish
You can buy it Target 28.36 stop loss 24.56 money management is your responsibility . good luck
Biotech that's showing tremendous relative strength against this bear market. Worth putting on your watchlist.
ALKS: Alkermes plc 2021-10-25 07:00:00 Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
ALKS is about to breakout. I will be long some before the actual break occurs. Once break occurs I am expecting a run to at least 30.0.
Hey traders, ALKERMES is in a bearish fake dynamic with a low volume of issued sales and refusal of buyers on the shadow. On the TIMEFRAME M1 we observed a tombstone with a high volume of purchases made it will breakout its consolidation zone down. To go on its last precedent lower and turn around big propability to breakout the price. Subsequently the VWAP will...
Ascending Triangle, Confirmed Pros R/R above7 Descending Volume PPS above 50M and 200MA Cons 200MA descending ATR flat 250RSI below 50 Targets: PT1 = 20,96 PT2 = 23,43 PT3 = 24,79
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
BUY signal at 20.98 $ Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. If you want to see more history of this strategy, I will able to show you if you request me. ATTENTION this strategy may...
Nice volume bars this past week, appears to be consolidating for a move up. Looking at August calls in this name.
Investors once again are disappointing by the lack of progress in Alkermes Plc and have hit the sell button today. Indications are that the sell side will continue, technical levels have been broken and there is not great support under to halt the action .